Your session is about to expire
← Back to Search
Educational Video for Latent Tuberculosis
N/A
Waitlist Available
Research Sponsored by Kaiser Permanente
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Receipt of an LTBI treatment prescription order with specific medication ID codes for Isoniazid, Rifampin, Isoniazid + Rifampin, and Isoniazid + Rifapentine
Age ≥18 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year after treatment prescription
Awards & highlights
No Placebo-Only Group
Summary
This trial will test whether a 3-minute educational video can improve treatment completion rates for latent tuberculosis.
Who is the study for?
Adults who are members of Kaiser Permanente Southern California, diagnosed with latent tuberculosis (LTBI), and have been prescribed treatment. Participants must be at least 18 years old and not have an active TB diagnosis.
What is being tested?
The trial is testing if a short educational video sent to patients via text or email can increase the completion rates of LTBI treatment compared to standard care without the video. Patients will be randomly assigned to either receive the video or continue with standard care.
What are the potential side effects?
Since this intervention involves watching an educational video, there are no direct medical side effects associated with it. However, participants' perceptions and engagement with the video content will be evaluated.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been prescribed medication for latent TB infection.
Select...
I am 18 years old or older.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year after treatment prescription
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year after treatment prescription
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Treatment completion
Secondary study objectives
Treatment completion by treatment regimen
Treatment initiation
Treatment initiation by treatment regimen
+3 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: LTBI video interventionExperimental Treatment1 Intervention
Patients randomized to the intervention group will be sent an invitation with a link to watch a brief (\~3 minute video) about the importance of taking and completing LTBI treatment.
Group II: Standard careActive Control1 Intervention
Patients who are randomized to receive standard of care will not receive any messages or have any contact with the research team.
Find a Location
Who is running the clinical trial?
Kaiser PermanenteLead Sponsor
554 Previous Clinical Trials
27,729,852 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have been prescribed medication for latent TB infection.I am 18 years old or older.
Research Study Groups:
This trial has the following groups:- Group 1: Standard care
- Group 2: LTBI video intervention
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.